Oncology Central

ASCO18: High dose of Nexium® with aspirin reduces risk of developing esophageal cancer

A Phase III randomized trial has demonstrated that taking a high dose of the acid-reducing medicine esomeprazole (Nexium®) with low dose aspirin for a minimum of 7 years can reduce the risk of developing esophageal cancer, a pre-cancerous lesion termed high-grade dysplasia or delay death from any cause in people with Barrett’s esophagus. This rare condition increases the risk of esophageal disease by 50-fold.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.